AMA grants Cardio Diagnostics CPT PLA reimbursement code for Epi+Gen CHD

Cardio Diagnostics Holdings announced that the American Medical Association AMA has granted and assigned a dedicated Current Procedural Terminology Proprietary Laboratory Analysis code, 0439U, for the company’s AI-driven coronary heart disease CHD event risk assessment test, Epi+Gen CHD… Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only AI-powered integrated genetic-epigenetic clinical blood test for evaluating the likelihood of a patient experiencing a CHD event, mainly a heart attack, within the next three years….Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD In peer-reviewed studies, Epi+Gen CHD was more cost-effective and more sensitive for assessing heart attack risk compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. “Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. For employers, this means potentially greater access to a technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks.